Related Experiment Video

Updated: Jun 27, 2025

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

843

Novel Dry Hyaluronic Acid-Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with

María S Magi1,2, Yanina de Lafuente1,2, Eride Quarta3

  • 1Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (UNC), Córdoba X5000GYA, Argentina.

Pharmaceutics
|April 27, 2024
PubMed

Insights

Hyaluronic acid-vancomycin complexes offer a promising inhalable formulation for cystic fibrosis patients. This novel approach enhances drug delivery to the lungs, maintaining antibacterial efficacy against Staphylococcus aureus.

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems
  • Biomaterials

Background:

  • Vancomycin (VAN) is crucial for treating methicillin-resistant Staphylococcus aureus pulmonary infections in cystic fibrosis patients.
  • Intravenous administration of VAN leads to adverse effects; intrapulmonary delivery is a potential alternative.
  • No inhalable VAN formulations are currently available commercially.

Purpose of the Study:

  • To prepare and characterize an ionic complex of hyaluronic acid (HA) and vancomycin (VAN) for inhalable formulations.
  • To evaluate the aerosolization, aerodynamic performance, and drug release profile of the HA-VAN complex.
  • To confirm the antibacterial efficacy of VAN within the developed complex.

Main Methods:

  • Spray drying was used to create a particulate-solid HA-VAN complex.
  • Fourier Transform Infrared (FTIR) spectroscopy and thermal analysis confirmed ionic interactions.
  • X-ray diffraction analyzed the complex's structural properties.
  • In vitro drug release studies and microbiological assays were performed.

Main Results:

  • The HA-VAN complex demonstrated ionic interaction between HA and VAN and an amorphous structure.
  • The powder exhibited suitable aerosolization and aerodynamic properties for deep lung delivery.
  • An extended in vitro release of VAN exceeding 24 hours was observed.
  • The complex maintained VAN's antibacterial efficacy against Staphylococcus aureus strains.

Conclusions:

  • The developed HA-VAN complex shows potential for inhalable formulations.
  • This formulation may offer improved efficacy and safety compared to conventional VAN treatments.
  • Further development could lead to a viable alternative for pulmonary infections.
Keywords:
cystic fibrosishyaluronic acidinhalable vancomycinpolyelectrolyte–drug complexpulmonary infection

More Related Videos

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.7K
Intratracheal Administration of Dry Powder Formulation in Mice07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

10.4K

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
255
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
157
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
276
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
338
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
239
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
136